MGI Pharma Inc. (NASDAQ:MOGN) of Minneapolis announcedWednesday that it has granted European rights for Salagen toEurocetus BV of Amsterdam, the Netherlands. Salagen(pilocarpine) is a potential treatment for the severe dry mouththat results from radiation used to treat head and neck cancer.The countries included in this collaborative agreement includeall members of the European Community, the countries in theEuropean Free Trade Association and the former Eastern Bloccountries in Europe.

(c) 1997 American Health Consultants. All rights reserved.

No Comments